SANOFI ADR

NASDAQ: SNY (Sanofi)

最近更新时间: 07 Mar, 9:18PM

59.25

-0.17 (-0.29%)

前收盘价格 59.42
收盘价格 59.15
成交量 3,311,340
平均成交量 (3个月) 2,554,861
市值 148,550,418,432
市盈率 (P/E TTM) 25.00
预期市盈率 (P/E Forward) 12.50
价格/销量 (P/S) 2.95
股市价格/股市净资产 (P/B) 1.64
52周波幅
45.22 (-23%) — 59.72 (0%)
利润日期 24 Apr 2025
股息率 (DY TTM) 6.88%
营业毛利率 12.56%
营业利益率 (TTM) 13.99%
稀释每股收益 (EPS TTM) 2.36
季度收入增长率 (YOY) -3.10%
季度盈利增长率 (YOY) 11.50%
总债务/股东权益 (D/E MRQ) 23.01%
流动比率 (MRQ) 1.46
营业现金流 (OCF TTM) 9.08 B
杠杆自由现金流 (LFCF TTM) -4.94 B
资产报酬率 (ROA TTM) 4.28%
股东权益报酬率 (ROE TTM) 7.30%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看涨 看涨
Drug Manufacturers - General (全球的) 看涨 看涨
股票 Sanofi 看涨 看涨

AIStockmoo 评分

-0.5
分析师共识 1.5
内部交易活动 NA
价格波动 -3.0
技术平均移动指标 0.0
技术振荡指标 -0.5
平均 -0.50

相关股票

股票 市值 DY P/E(TTM) P/B
SNY 149 B 6.88% 25.00 1.64
AZN 228 B 2.11% 32.67 6.19
AMGN 166 B 2.95% 41.04 27.94
GILD 141 B 2.74% 298.29 7.22
GRFS 7 B - 33.72 0.780
BIIB 21 B - 12.64 1.20

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Core
机构持股比例 10.61%

所有权

姓名 日期 持有股份
Mondrian Investment Partners Ltd 31 Dec 2024 3,453,122
52周波幅
45.22 (-23%) — 59.72 (0%)
65.00 (9.71%)
总计 1 保留
公司 日期 目标价格 调整类型 价格@调整类型
Goldman Sachs 21 Mar 2025 65.00 (9.70%) 保留 56.90

该时间范围内无数据。

日期 类型 细节
03 Apr 2025 公告 Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03 Apr 2025 公告 Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03 Apr 2025 公告 Sanofi: Information concerning the total number of voting rights and shares - February 2025
28 Mar 2025 公告 Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28 Mar 2025 公告 Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28 Mar 2025 公告 Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
28 Mar 2025 公告 Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
26 Mar 2025 公告 Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
26 Mar 2025 公告 Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
25 Mar 2025 公告 Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
25 Mar 2025 公告 Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
24 Mar 2025 公告 Press Release: Availability of the Q1 2025 Aide mémoire
24 Mar 2025 公告 Press Release: Availability of the Q1 2025 Aide mémoire
20 Mar 2025 公告 Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20 Mar 2025 公告 Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
14 Mar 2025 公告 Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
08 Mar 2025 公告 Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
08 Mar 2025 公告 Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
05 Mar 2025 公告 Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
05 Mar 2025 公告 Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
25 Feb 2025 公告 Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
25 Feb 2025 公告 Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
22 Feb 2025 公告 Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
22 Feb 2025 公告 Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
22 Feb 2025 公告 Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
19 Feb 2025 公告 Press Release: Sanofi and CD&R sign Opella share purchase agreement
19 Feb 2025 公告 Press Release: Sanofi and CD&R sign Opella share purchase agreement
18 Feb 2025 公告 Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
18 Feb 2025 公告 Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
13 Feb 2025 公告 Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
13 Feb 2025 公告 Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
13 Feb 2025 公告 Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
13 Feb 2025 公告 Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
07 Feb 2025 公告 Press Release: Execution of a share buyback agreement for up to €2 billion
07 Feb 2025 公告 Press Release: Execution of a share buyback agreement for up to €2 billion
07 Feb 2025 公告 Press Release: Execution of a share buyback agreement for up to €2 billion
03 Feb 2025 公告 Press Release: Sanofi announces buy back of shares from L’Oréal
03 Feb 2025 公告 Press Release: Sanofi announces buy back of shares from L’Oréal
31 Jan 2025 公告 Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
31 Jan 2025 公告 Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
30 Jan 2025 公告 Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
30 Jan 2025 公告 Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
29 Jan 2025 公告 Sanofi: Information concerning the total number of voting rights and shares - December 2024
22 Jan 2025 公告 Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
22 Jan 2025 公告 Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
21 Jan 2025 公告 Press Release: Opella reaches study milestone for Cialis
21 Jan 2025 公告 Press Release: Opella reaches study milestone for Cialis
15 Jan 2025 公告 Sanofi: Information concerning the total number of voting rights and shares – November 2024
13 Jan 2025 公告 Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
13 Jan 2025 公告 Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
13 Jan 2025 CNBC Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion
09 Jan 2025 公告 Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
09 Jan 2025 公告 Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
显示更多
股息率 (DY TTM) 6.88%
5年平均股息收益率 4.78%
股息支付比率 85.70%
除息日 公告日期 支付日期 详情
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 现金
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 现金
30 May 2023 - 23 Jun 2023 1.9000852 现金
26 May 2022 - 27 Jun 2022 0.2971788 现金
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 现金
03 May 2021 23 Mar 2021 26 May 2021 1.906064 现金
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 现金
07 May 2019 - 31 May 2019 1.722322 现金
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 现金
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 现金
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 现金
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 现金
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 现金
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 现金
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 现金
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票